{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:37:09Z","timestamp":1785897429101,"version":"3.56.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115374","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T06:55:33Z","timestamp":1742626533000},"page":"115374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CAR-T cell therapy for patients with extramedullary multiple myeloma\uff1aOpportunities and challenges"],"prefix":"10.1016","volume":"220","author":[{"given":"Yin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2025.115374_bib1","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.immuni.2023.09.010","article-title":"Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy","volume":"56","author":"Singh","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01109-y","article-title":"Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond","volume":"14","author":"Su","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2025.115374_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2025.115374_bib8","article-title":"Integrated transcriptomic analysis reveals a distinctive role of YAP1 in extramedullary invasion and therapeutic sensitivity of multiple myeloma","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115374_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.ejca.2025.115374_bib10","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1097\/CM9.0000000000002351","article-title":"Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.ejca.2025.115374_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2022.2113772","article-title":"Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma","volume":"15","author":"Chen","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ejca.2025.115374_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.12688\/f1000research.109551.1","article-title":"Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease","volume":"11","author":"Hirao","year":"2022","journal-title":"F1000Res"},{"key":"10.1016\/j.ejca.2025.115374_bib13","article-title":"Intratumor heterogeneity of MIF expression correlates with extramedullary involvement of multiple myeloma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115374_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw131","article-title":"Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response","volume":"108","author":"Zheng","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ejca.2025.115374_bib15","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNF\u03b1","volume":"5","author":"Akhmetzyanova","year":"2021","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.ejca.2025.115374_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314765","article-title":"Involvement of small non-coding RNA and cell antigens in pathogenesis of extramedullary multiple myeloma","volume":"23","author":"Vlachova","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2022.2164449","article-title":"Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis","volume":"28","author":"Chen","year":"2023","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.ejca.2025.115374_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14882","article-title":"Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma","volume":"179","author":"Handa","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115374_bib19","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.prp.2018.08.018","article-title":"Association of increased microvessel density with skeletal extramedullary disease relapse in multiple myeloma patients who have skeletal extramedullary disease at diagnosis","volume":"214","author":"Yang","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ejca.2025.115374_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941437","article-title":"Molecular impact of the tumor microenvironment on multiple myeloma dissemination and extramedullary disease","volume":"12","author":"Forster","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","article-title":"Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion","volume":"26","author":"Ryu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.32604\/biocell.2023.046640","article-title":"Immune checkpoint receptors and their ligands on CD8 T cells and myeloma cells in extramedullary multiple myeloma","volume":"48","author":"Zhang","year":"2024","journal-title":"Biocell"},{"key":"10.1016\/j.ejca.2025.115374_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13981","article-title":"Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: a CMWP-EBMT study","author":"Gagelmann","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2025.115374_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221109500","article-title":"Bone-related extramedullary disease in newly diagnosed myeloma patients is an independent poor prognostic predictor","volume":"16","author":"Wang","year":"2022","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","article-title":"Limited efficacy of daratumumab in multiple myeloma with extramedullary disease","volume":"36","author":"Jelinek","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2025.115374_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115374_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ejca.2025.115374_bib28","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.115374_bib30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2025.115374_bib31","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115374_bib32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib33","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.ejca.2025.115374_bib34","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C Group 5 Member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2025.115374_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.115374_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: a single center analysis of two clinical trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"issue":"ement 1","key":"10.1016\/j.ejca.2025.115374_bib38","article-title":"Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease","volume":"142","author":"Pan","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.ejca.2025.115374_bib39","article-title":"Clinical efficacy observation of humanized BCMA-CAR-T in the treatment of relapsed\/refractory multiple myeloma complicated with extramedullary lesions","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.115374_bib40","article-title":"Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"issue":"ement 1","key":"10.1016\/j.ejca.2025.115374_bib41","article-title":"Integrated analysis of B-Cell maturation antigen-specific CAR T Cells (CT053) in relapsed and refractory multiple myeloma subjects by high-risk factors","volume":"138","author":"Fu","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejca.2025.115374_bib42","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115374_bib43","article-title":"A five-year follow-up clinical study of the B cell maturation antigen chimeric antigen receptor-T cell therapy HDS269B in patients with relapsed or refractory multiple myeloma","author":"Chen","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2025.115374_bib45","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283888","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience","author":"Hashmi","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04655-w","article-title":"A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ejca.2025.115374_bib50","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2025.115374_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-Cell Maturation Antigen\/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.ejca.2025.115374_bib53","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115374_bib54","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115374_bib55","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Holly","year":"2023","journal-title":"PubMed"},{"issue":"14","key":"10.1016\/j.ejca.2025.115374_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411259","article-title":"Genetic Abnormalities in Extramedullary Multiple Myeloma","volume":"24","author":"McAvera","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2025.115374_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2025.115374_bib58","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115374_bib59","first-page":"811","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023"},{"issue":"7","key":"10.1016\/j.ejca.2025.115374_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115374_bib61","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","article-title":"Granzyme B-activated IL18 potentiates \u03b1\u03b2 and \u03b3\u03b4 CAR T cell immunotherapy in a tumor-dependent manner","volume":"32","author":"Hull","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2025.115374_bib62","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"0","author":"Yang","year":"2024","journal-title":"PubMed"},{"issue":"750","key":"10.1016\/j.ejca.2025.115374_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7640","article-title":"Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics","volume":"16","author":"Korell","year":"2024","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.115374_bib64","article-title":"The BTLA-HVEM axis restricts CAR T cell efficacy in cancer","volume":"25","author":"Puneeth","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2025.115374_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.05.017","article-title":"BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism","author":"Yang","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.ejca.2025.115374_bib66","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","article-title":"GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol Ther"},{"issue":"8010","key":"10.1016\/j.ejca.2025.115374_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"issue":"8010","key":"10.1016\/j.ejca.2025.115374_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2025.115374_bib69","article-title":"GSNOR overexpression enhances CAR-T cell stemness and anti-tumor function by enforcing mitochondrial fitness","volume":"32","author":"Qing","year":"2024","journal-title":"PubMed"},{"issue":"3","key":"10.1016\/j.ejca.2025.115374_bib70","first-page":"213","article-title":"SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors","volume":"21","author":"Liang","year":"2024","journal-title":"PubMed"},{"issue":"6","key":"10.1016\/j.ejca.2025.115374_bib71","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2024.0473","article-title":"Allogeneic CD19\/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia","volume":"100","author":"Phely","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib72","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib73","article-title":"Time to abandon CAR-T monotherapy for solid tumors","volume":"1878","author":"Yin","year":"2023","journal-title":"Biochim Et Biophys Acta (BBA) - Rev Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115374_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115374_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109167","article-title":"Inducing vascular normalization: A promising strategy for immunotherapy","volume":"112","author":"Luo","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib76","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3892\/ijmm.2016.2724","article-title":"Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review)","volume":"38","author":"Wang","year":"2016","journal-title":"Int J Mol Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.115374_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115374_bib78","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ejca.2025.115374_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2025.115374_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107186","article-title":"Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects","volume":"203","author":"Zhu","year":"2024","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib81","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03648-y","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Cancer Immunol, Immunother"},{"issue":"8","key":"10.1016\/j.ejca.2025.115374_bib82","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14737140.2023.2229029","article-title":"Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy","volume":"23","author":"Yao","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"14","key":"10.1016\/j.ejca.2025.115374_bib83","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"issue":"ement 1","key":"10.1016\/j.ejca.2025.115374_bib84","article-title":"Efficacy and Safety of BCMA-Specific CAR T Cell-Based Therapy in Relapsed\/Refractory Multiple Myeloma Patients with Extramedullary Disease","volume":"142","author":"Qi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.115374_bib85","article-title":"Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy","author":"Yang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115374_bib86","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","author":"Hou","year":"2024","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115374_bib87","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.115374_bib88","article-title":"CAR T cell membrane camouflaged nanocatalyst augments CAR T cell therapy efficacy against solid tumor","volume":"0","author":"Wenjing","year":"2024","journal-title":"PubMed"},{"issue":"9","key":"10.1016\/j.ejca.2025.115374_bib89","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/Anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115374_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01216-4","article-title":"Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells","author":"Zhang","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae018","article-title":"Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor","volume":"11","author":"Liao","year":"2024","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.ejca.2025.115374_bib92","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022682","article-title":"CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models","author":"Brinkmann","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.115374_bib93","article-title":"Rituximab potentially improves clinical outcomes of CAR-T therapy for r\/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion","author":"Li","year":"2024","journal-title":"Cell Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008857","article-title":"Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma","volume":"12","author":"Liu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115374_bib95","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015285","article-title":"Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma","author":"Waldschmidt","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ejca.2025.115374_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2025.115374_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2024.101077","article-title":"Heat-inducible CAR-T overcomes adverse mechanical tumor microenvironment in a 3D bioprinted glioblastoma model","author":"Tang","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.ejca.2025.115374_bib98","article-title":"Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma","author":"Zugasti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2025.115374_bib99","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determine myeloma CAR-T outcomes","author":"Freeman","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejca.2025.115374_bib100","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1007\/s00259-022-05923-5","article-title":"Feasibility of in vivo CAR T cells tracking using streptavidin\u2013biotin-paired positron emission tomography","volume":"49","author":"Pan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:49:22Z","timestamp":1760640562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":100,"alternative-id":["S0959804925001558"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115374","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for patients with extramedullary multiple myeloma\uff1aOpportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115374"}}